Welcome to the Champions Portal

The UK Charity for TNBC recently attended AstraZeneca’s Advocacy Leaders Summit alongside other UK charities large and small, helping to ensure the voice of the TNBC community was represented in wider discussions around cancer care, collaboration and the Government’s Cancer Plan.

The UK Charity for TNBC joined House of Hope Scotland in Edinburgh for its first dedicated TNBC meet-up, bringing people together to share experiences, connect with others and have open conversations about life after a TNBC diagnosis.

The landmark UK TNBC Symposium 2026 will bring together clinicians, researchers and healthcare professionals for a dedicated discussion on progress in triple negative breast cancer treatment, care and research.

The UK Charity for TNBC is proud to partner with The House of Hope Scotland. Founder Robin Woolcock will attend the organisation’s first TNBC support group in Edinburgh on Tuesday 25 August, and people affected by triple negative breast cancer are warmly invited to join.

Members of The UK Charity for TNBC’s Patient Advisory Panel came together in person for the first-ever PAP meet-up in London - an evening filled with connection, shared experiences, support and a strong sense of community.

The UK Charity for TNBC is excited to announce the first face-to-face meet-up for existing members of the Patient Advisory Panel (PAP) on Thursday the 2nd of July at Future Dreams House in King’s Cross, London.

The UK Charity for TNBC would like to congratulate Maggie’s as it celebrates 30 years of supporting people affected by cancer.

What does the new National Cancer Plan mean for people with triple negative breast cancer (TNBC)? Our latest update explains the potential impact on care and treatment.

Robin Woolcock, founder of the UK Charity for Triple Negative Breast Cancer, joins LACE Partners’ podcast to raise awareness of TNBC and spark vital conversations about how workplaces can better support those affected.

The UK Charity for Triple Negative Breast Cancer (TNBC) recently asked our Patient Advisory Panel (PAP) members a series of important questions on behalf of the pharmaceutical company BioNTech. Their answers provided critical information which will now be used by BioNTech to help inform the design of a trial for an investigational drug intended for people with the metastatic form of TNBC. 

New NICE guidance on TNBC treatment reflects input from The UK Charity for TNBC’s Patient Advisory Panel (PAP). Your involvement is helping to shape more effective care for those affected by TNBC.

The UK Charity for TNBC attended ESMO Breast 2025 in Munich, presenting a poster, ‘Needs of People with Triple Negative Breast Cancer (TNBC): The Patients Voice’, based on roundtable discussions in partnership with RCNi, produced by Dr Hira Yousef and Professor Chris Twelves.